311 results on '"Ilancheran A"'
Search Results
2. Bimetallic Metal-Organic Framework: An Efficient Electrocatalyst for Bromine based Flow Batteries
3. Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01)
4. Bimetallic metal–organic framework: an efficient electrocatalyst for bromine-based flow batteries.
5. The use of video laryngoscopy outside the operating room: A systematic review
6. Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies
7. Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer?
8. Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
9. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients
10. Self-sampling HPV DNA test for cervical cancer screening in Singapore: A prospective study
11. Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) (165)” [Gynecologic Oncology Volume 166, Supplement 1, August 2022, Page S98]
12. Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer?
13. Self-sampling HPV DNA test for cervical cancer screening in Singapore: A prospective study
14. The use of video laryngoscopy outside the operating room: A systematic review
15. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
16. Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) (165)
17. PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
18. Successful hyperbaric oxygen treatment of a patient with a HeartMate III left ventricular assist device.
19. Corrigendum to 'Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) (165)' [Gynecologic Oncology Volume 166, Supplement 1, August 2022, Page S98]
20. Malignant ovarian germ-cell tumours
21. Gynaecological cancer in pregnancy
22. Epithelial ovarian cancer
23. GESTATIONAL TROPHOBLASTIC DISEASE
24. CARCINOMA OF THE OVARY
25. Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) (165)
26. Cervical dysplasia: Assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy
27. PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
28. Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV‐16/18 antibodies
29. Should emergency medicine registrars focus on seeing patients and leave the teaching of medical students to others? Yes
30. Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009
31. Human Fetal Membranes: A Source of Stem Cells for Tissue Regeneration and Repair?
32. Stem cell properties of human amniotic epithelial cells
33. The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer
34. 9.1 - Approach to undifferentiated fever in adults
35. 7.5 - Gastroenteritis
36. High wavenumber Raman spectroscopy for in vivo detection of cervical dysplasia
37. Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01)
38. Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
39. 835P Clinical outcomes of advanced/ recurrent ovarian clear cell carcinoma in a multi-ethnic Asian cohort following bevacizumab and immune checkpoint inhibitor therapy
40. Clinical outcomes of MSI-high (MSI-H) versus stable (MSS) endometrial carcinoma (EC) after front-line platinum chemotherapy and subsequent matched therapy.
41. Human Amnion Epithelial Cell Transplantation Abrogates Lung Fibrosis and Augments Repair
42. Clinical validation of GAGE family protein as a biomarker for radiotherapy resistance in cervical cancer.
43. Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel (wP) for platinum resistant ovarian cancer (PROC)
44. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients
45. HUMAN AMNION EPITHELIAL STEM CELLS ABROGATE FIBROSIS AND AUGMENT LUNG REPAIR: TO 09
46. Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer?
47. The Association between Fibrinogen, von Willebrand Factor, Antithrombin III, and D-dimer Levels and Survival Outcome by 36 Months from Ovarian Cancer
48. Primary peritoneal serous carcinoma
49. Percutaneous dilatation of benign ureteric structures following radical hysterectomy
50. 835P Clinical outcomes of advanced/ recurrent ovarian clear cell carcinoma in a multi-ethnic Asian cohort following bevacizumab and immune checkpoint inhibitor therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.